Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Vraylar for Schizophrenia in Adults

Allergan plc news release; 2017 Nov 13

Publish date:: November 30, 2017

Allergan plc has announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for the maintenance treatment of adults with schizophrenia. Vraylar is also approved in the US in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder. Allergan plc is headquartered in Dublin, Ireland.

Dosage/administration: For schizophrenia, Vraylar should be administered once daily, with or without food. The starting dose is 1.5 mg/day; recommended dose is 1.5 mg to 6 mg/day.

Adverse effects: The most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) for patients taking Vraylar for schizophrenia were extrapyramidal symptoms and akathisia.

Citation:

Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia. [news release] Dublin, Ireland: Allergan plc. November 13, 2017. https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Receives-FDA-Approval-For-Use-of-VRAYLAR. Accessed November 14, 2017.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in FDA Actions

FDA Approves Cassipa for Opioid Addiction Treatment , FDA news release; 2018 Sep 7

FDA Approves Marketing of OCD Treatment Device, FDA Web site; 2018 Aug 17

FDA Approves Perseris for Schizophrenia, FDA news release; 2018 Jul 27

FDA Approves New Dosing Formulation for Nuplazid, Acadia Pharmaceuticals Inc. news release; 2018 Jun 29

FDA Approves Initiation Drug for Schizophrenia, Alkermes plc news release; 2018 Jul 2